A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.

Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Mar 2002Cited by 57 (Europe PMC)

PMID11874243DOI10.1359/jbmr.2002.17.3.521PepBankPUB-11874243

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with idiopathic osteoporosis, salmon calcitonin increased lumbar BMD more than placebo.
In plain wordsIn men with idiopathic osteoporosis, salmon calcitonin increased lower spine bone density more than placebo.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine BMD
Study
n = 28
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 12 monthsAs given in this study (human).
Measurements
Lumbar BMD increase
7.1%
calcitonin
SEM
1.7%
calcitonin
Lumbar BMD increase
2.4%
placebo
SEM
1.5%
placebo
P
< 0.05
calcitonin versus placebo, lumbar BMD increase
P
> 0.05
placebo versus baseline
Source sentences
Summary
The men who received SCT had a mean (+/-SEM) increase in BMD of 7.1 +/- 1.7% at the lumbar spine.
3 context sentences(design, population, supporting numbers)
Summary · context
In contrast, the men who received the placebo had an increase of 2.4 +/- 1.5% (p > 0.05) for the comparison with baseline.
Summary · context
The increase in lumbar BMD in the calcitonin group was significantly greater than that in the placebo group (p < 0.05).
Summary · context
Twenty-eight men with idiopathic osteoporosis aged 27-74 years (mean, 52.4 years) were randomized to receive either nasal SCT (200 IU) or a nasal placebo daily for a period of 1 year.
Report a problemFND-1187424301
02HumanRandomized controlled trialEfficacy outcome
In men with idiopathic osteoporosis, salmon calcitonin did not significantly change femoral neck, trochanter or Ward's triangle BMD relative to baseline or placebo.
In plain wordsIn men with osteoporosis, salmon calcitonin did not significantly change bone density at three hip sites relative to baseline or placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeFemoral neck, trochanter and Ward's triangle BMD
Study
n = 28
Comparator
Baseline and placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 12 monthsAs given in this study (human).
Source sentences
Summary
There were no significant changes in the femoral neck, trochanter, or Ward's triangle relative to both baseline and placebo after 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
In a 12-month randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover.
Summary · context
Twenty-eight men with idiopathic osteoporosis aged 27-74 years (mean, 52.4 years) were randomized to receive either nasal SCT (200 IU) or a nasal placebo daily for a period of 1 year.
Report a problemFND-1187424302
03HumanRandomized controlled trialEfficacy outcome
In men with idiopathic osteoporosis, salmon calcitonin suppressed bone resorption markers and, less strongly, bone formation markers, unlike placebo.
In plain wordsSalmon calcitonin suppressed bone breakdown markers and, less strongly, bone formation markers, unlike placebo.
Peptide
Calcitonin-salmon
Outcome
DecreaseBone turnover markers
Study
n = 28
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 12 monthsAs given in this study (human).
Source sentences
Summary
Treatment with nasal SCT resulted in a significantly pronounced suppression of bone resorption markers
2 context sentences(design, population, supporting numbers)
Summary · context
and to a lesser extent in bone formation markers (serum bone-specific alkaline phosphatase [BALP], osteocalcin [OC], serum C-terminal procollagen type I extension peptides [PICP], and serum N-termnal procollagen type I extension peptides [PINP]), whereas the placebo did not.
Summary · context
Twenty-eight men with idiopathic osteoporosis aged 27-74 years (mean, 52.4 years) were randomized to receive either nasal SCT (200 IU) or a nasal placebo daily for a period of 1 year.
Report a problemFND-1187424303
04HumanNon-randomized trialSafety outcome
In men with idiopathic osteoporosis, salmon calcitonin caused no reported treatment-related adverse events.
In plain wordsMen who received salmon calcitonin had no reported treatment-related adverse events.
Peptide
Calcitonin-salmon
Outcome
Not applicableTreatment-related adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
200 IU daily · intranasal · 12 monthsAs given in this study (human).
Source sentences
Summary
Therapy was tolerated well and there were no treatment-related adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
In a 12-month randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover.
Summary · context
Twenty-eight men with idiopathic osteoporosis aged 27-74 years (mean, 52.4 years) were randomized to receive either nasal SCT (200 IU) or a nasal placebo daily for a period of 1 year.
Report a problemFND-1187424304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.